NKGen Biotech (NKGN) Stock Price, News & Analysis

Company Overview

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Key Stats

• Today's Range: $0.31 to $0.35
• 50-Day Range: $0.23 to $0.77
• 52-Week Range: $0.20 to $4.06
• Volume: 124,514 shs
• Average Volume: 1.77 million shs
• Market Capitalization: $11.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NKGN Stock Analysis - Frequently Asked Questions

How have NKGN shares performed this year?

NKGen Biotech's stock was trading at $2.75 on January 1st, 2024. Since then, NKGN stock has decreased by 88.6% and is now trading at $0.3129.
View the best growth stocks for 2024 here.

How were NKGen Biotech's earnings last quarter?

NKGen Biotech, Inc. (NYSE:NKGN) announced its quarterly earnings results on Thursday, September, 12th. The company reported ($0.67) earnings per share (EPS) for the quarter.

Who are NKGen Biotech's major shareholders?

NKGen Biotech's top institutional investors include Polar Asset Management Partners Inc. (3.34%) and Sequoia Financial Advisors LLC (0.27%). Insiders that own company stock include Paul Y Song and James A Graf.
View institutional ownership trends.

How do I buy shares of NKGen Biotech?

Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NKGen Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI).

Company Calendar

• Last Earnings: 9/12/2024
• Today: 11/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NKGN
• Previous Symbol: NYSE:NKGN
• CUSIP: N/A
• CIK: 1845459
• Web: nkgenbiotech.com
• Phone: 949-396-6830
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-82,940,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -479.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: $80,000.00
• Price / Sales: 149.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.68) per share
• Price / Book: -0.13

Miscellaneous

• Outstanding Shares: 35,360,000
• Free Float: 8,964,000
• Market Cap: $11.94 million
• Optionable: Not Optionable
• Beta: 0.53